Education
About Us
Working with TipRanks
Follow Us
SenesTech Inc (SNES)
NASDAQ:SNES
Top Page
SenesTech
(NASDAQ:SNES)
48Neutral
SenesTech (SNES) vs. S&P 500 (SPY)
Market Cap
$3.28M
Dividend YieldN/A
Average Volume (3M)184.15K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth55.66%
EPS Growth96.71%
CountryUS
Employees23
SectorBasic Materials
Sector Strength59
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-9.93
Shares Outstanding1,746,930
10 Day Avg. Volume40,179
30 Day Avg. Volume184,147
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.04
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside431.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
SenesTech Business Overview & Revenue Model
Company DescriptionSenesTech, Inc. is a biotechnology company that focuses on developing sustainable solutions for pest management. The company operates within the sectors of agriculture and pest control, offering innovative products designed to curb rodent populations humanely and effectively. Its flagship product, ContraPest, is a revolutionary rodent fertility control bait that targets the reproductive capabilities of rodents, reducing their population growth over time without harmful side effects on non-target species or the environment.
How the Company Makes MoneySenesTech generates revenue through the sale of its primary product, ContraPest, which is distributed to various sectors, including agriculture, municipalities, and commercial enterprises that require effective rodent management solutions. The company partners with pest management professionals and distribution networks to expand the reach of its product. SenesTech's earnings are influenced by factors such as regulatory approvals, market demand for humane and environmentally friendly pest control solutions, and the expansion of its distribution channels.
SenesTech Financial Statement Overview
Summary
SenesTech shows potential with its revenue growth and stable balance sheet, but continues to face significant challenges in achieving profitability and positive cash flows. The company's financial health is hampered by ongoing net losses and negative cash flow, necessitating a strategic focus on operational efficiency and cost management to improve financial performance.Income Statement
SenesTech has shown some revenue growth, with a significant increase from $1,193,000 in 2023 to $1,857,000 in 2024. However, the company is still struggling with profitability, as evidenced by the negative EBIT and net income. The gross profit margin has improved, but the net profit margin remains non-existent due to zero net income in 2024. These factors result in a moderate score, reflecting positive revenue trends but ongoing profitability challenges.45
Neutral
Balance Sheet
The balance sheet indicates a stable equity position with a decrease in total liabilities over the years. The debt-to-equity ratio is low, showing conservative leverage. However, the return on equity is weak due to persistent net losses, limiting the score to an average level. The company's financial stability is supported by a solid equity base, but profitability issues weigh heavily.50
Neutral
Cash Flow
SenesTech's cash flow statement reveals challenges with negative operating and free cash flows, despite some improvement in free cash flow from 2023 to 2024. The operating cash flow to net income ratio cannot be calculated for 2024 due to zero net income. The company has relied on financing activities to manage cash needs, reflecting ongoing cash flow struggles and reducing the score.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.86M | 1.19M | 1.02M | 576.00K | 258.00K | Gross Profit |
| 1.00M | 539.00K | 464.00K | 220.00K | -23.00K | EBIT |
| -6.25M | -7.73M | -9.67M | -8.93M | -7.93M | EBITDA |
| -6.01M | -7.57M | -9.51M | -7.95M | -7.62M | Net Income Common Stockholders |
| -6.18M | -7.71M | -9.71M | -7.98M | -7.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.31M | 5.39M | 4.78M | 9.33M | 3.64M | Total Assets |
| 3.28M | 7.29M | 6.78M | 11.50M | 6.02M | Total Debt |
| 262.00K | 406.00K | 359.00K | 555.00K | 1.44M | Net Debt |
| -1.04M | -4.99M | -4.42M | -8.77M | -2.20M | Total Liabilities |
| 767.00K | 942.00K | 1.50M | 1.47M | 2.14M | Stockholders Equity |
| 2.51M | 6.35M | 5.28M | 10.04M | 3.88M |
| Cash Flow | Free Cash Flow | |||
| -6.12M | -7.71M | -8.75M | -7.88M | -7.22M | Operating Cash Flow |
| -6.03M | -7.57M | -8.58M | -7.78M | -7.11M | Investing Cash Flow |
| -56.00K | -149.00K | -170.00K | -99.00K | -67.00K | Financing Cash Flow |
| 2.00M | 8.34M | 4.20M | 13.56M | 8.88M |
SenesTech Technical Analysis
Negative
1.88
Price Trends
2.81
Negative
2.81
Negative
3.40
Negative
Market Momentum
-0.25
Positive
32.07
Neutral
4.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.81, and below the 200-day MA of 3.40, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 32.07 is Neutral, neither overbought nor oversold. The STOCH value of 4.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNES.
SenesTech Risk Analysis
SenesTech disclosed 33 risk factors in its most recent earnings report. SenesTech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SenesTech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (47)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.38B | 20.35 | 14.32% | 1.13% | -7.17% | -0.53% | |
52 Neutral | $6.98B | 46.40 | -10.11% | 1.24% | -19.08% | -136.41% | |
52 Neutral | $1.87B | ― | -16.38% | ― | -0.53% | -4131.19% | |
48 Neutral | $3.28M | ― | -139.56% | ― | 55.66% | 96.71% | |
47 Neutral | $2.66B | -3.14 | -22.17% | 3.33% | 3.73% | -29.29% | |
46 Neutral | $3.15B | ― | 4.98% | 4.82% | 3.61% | 94.27% |
* Basic Materials Sector Average
Performance Comparison
SNES
SenesTech
1.81
-5.19
-74.14%
AGCO
Agco
92.57
-23.87
-20.50%
LNN
Lindsay
126.52
12.23
10.70%
NEOG
Neogen
8.67
-6.41
-42.51%
SMG
Scotts Miracle-Gro Company
54.89
-14.16
-20.51%
SenesTech Earnings Call Summary
Earnings Call Date: Mar 12, 2025 | % Change Since: -18.26% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment with significant revenue growth, improved gross margins, and strategic initiatives aimed at achieving cash flow breakeven. While there are challenges such as product transition and regulatory delays, the overall outlook remains optimistic with multiple growth avenues in place.Highlights
Record Revenue Growth
SenesTech achieved a record quarterly revenue increase of 70% and an annual increase of 56%, driven largely by the Evolve product line.
Gross Margin Improvement
Gross profit margins improved to 61% from 44% in the previous year, highlighting operational efficiencies and higher margins from the Evolve product line.
E-commerce Sales Surge
E-commerce sales grew 206% year-over-year in Q4 2024, representing 55% of the company's Q4 revenue.
Municipal and International Expansion
Significant progress in municipal markets including orders from New York City and Baltimore, as well as international distribution agreements in 10 countries.
Strategic Financing
Completed a strategic financing initiative to raise $1 million with plans to raise an additional $4 million through short-term warrants, aimed at accelerating progress towards cash flow breakeven.
Operational Efficiencies
Cost reduction initiatives are expected to decrease cash burn by 30% per quarter, aiming for cash flow breakeven at $7 million annually, down from $12 million historically.
Lowlights
Decline in ContraPest Sales
Sales of the historical ContraPest product decreased by 51% as customers transition to the Evolve solutions.
Regulatory and Approval Delays
The need for state and local approvals and field trials presents challenges and delays in rolling out new product deployments, impacting the speed of revenue growth from new contracts.
Company Guidance
During the SenesTech Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call, the company provided guidance indicating significant progress towards achieving cash flow breakeven. Key metrics highlighted include a 70% increase in quarterly revenues and a quarterly gross profit margin of 61%, contributing to the smallest quarterly adjusted EBITDA loss in company history. The company aims to reduce annual cash burn by $2 million and anticipates lowering the revenue threshold for cash flow breakeven to $7 million annually, down from $12 million. This improvement is driven by their Evolve product line, which has seen substantial market acceptance, particularly in e-commerce, with online sales increasing by 206% year-over-year and representing 55% of Q4 2024 revenue. Additionally, the introduction of Evolve has expanded distribution into new retail and municipal markets and international territories. SenesTech is implementing several operational changes, such as pausing new product development and bringing certain functions in-house, to further optimize costs and support its path to profitability. The company expects these strategic initiatives, along with a recent $5 million strategic financing, to propel them towards achieving cash flow breakeven in the near term.SenesTech Corporate Events
Private Placements and Financing
SenesTech Secures $1.1M Through Warrant Agreements
Neutral
Mar 11, 2025
On March 9, 2025, SenesTech entered into agreements with holders of existing warrants to exercise their rights at a reduced price, generating approximately $1.1 million in gross proceeds. The company will issue new short-term warrants, potentially bringing in an additional $4.3 million if fully exercised, with the proceeds intended for working capital and general corporate purposes. The transactions are facilitated by H.C. Wainwright & Co., LLC, and are subject to customary closing conditions and stockholder approval. The new warrants are unregistered and will expire eighteen months after stockholder approval, with no active trading market expected for them.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.